theodi/ndl-core-corpus huggingface dataset:
wrans/answers2025-11-26 conversation_101
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_101

Wendy Morton:To ask the Secretary of State for Health and Social Care, what steps he is taking to help prevent industrial action in the NHS. \p Karin Smyth: In May, we accepted the independent pay review bodies’ headline pay recommendations, giving doctors and Agenda for Change staff, including nurses, an above inflation pay rise for the second year in a row.

As well as awarding resident doctors in England a pay rise of 28.9% over the last three years, we have listened to their concerns about the state of their training and employment for resident doctors and made proposals to tackle this. We have been clear that we cannot go further on pay but we remain committed to finding a way to end their dispute.

We continue to work in partnership with stakeholders, including trade unions and employers, to implement a suite of non-pay measures to improve working conditions such as tackling violence against National Health Service staff, improving career progression for nurses, and improving the process for exception reporting for resident doctors.

Our 10 Year Workforce Plan will set out how we will deliver change by making sure that staff are better treated, have better training, and more fulfilling roles.
wrans/answers2025-11-26 conversation_102
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_102

Mr Andrew Snowden:To ask the Secretary of State for Health and Social Care, what discussions his Department has had with the Academy of Medical Royal Colleges on overseas doctors competing for UK training posts. \p Karin Smyth: The Department has regular discussions with the Academy of Medical Royal Colleges about a range of issues, including recruitment to foundation and specialty training posts.
wrans/answers2025-11-26 conversation_103
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_103

Freddie van Mierlo:To ask the Secretary of State for Health and Social Care, pursuant to the answer of 8 October 2025 provided to question 76507, (i) how many NICE Technology Appraisal approved therapies are not being provided in contravention of obligations by a) Oxford University Hospitals NHS Foundation Trust b) Royal Berkshire Hospital NHS Foundation Trust, and c) Buckinghamshire Healthcare NHS Trust and (ii) what the names of these therapies are. \p Dr Zubir Ahmed: The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
wrans/answers2025-11-26 conversation_104
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_104

Mr Richard Holden:To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 November 2025 to Question 87431 on Congenital Abnormalities, what consanguinity data NHS England collects through the Maternity Services Data Set; what assessment he has made of the completeness and reliability of those data; and whether he has reviewed that information in his Department. \p Dr Zubir Ahmed: The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
wrans/answers2025-11-26 conversation_105
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_105

Mr Richard Holden:To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 November 2025 to Question 87431 on Congenital Abnormalities, whether he has plans to (a) publish aggregated consanguinity statistics collected through the Maternity Services Data Set, (b) improve the completeness and reliability of those data and (c) integrate consanguinity indicators into wider national population health or genomics datasets; and whether he has reviewed options for doing so in his Department. \p Karin Smyth: The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
wrans/answers2025-11-26 conversation_106
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_106

Jim McMahon:To ask the Secretary of State for Health and Social Care, what estimate has been made of the average number of lost work days for (a) public sector employees (b) private sector employees (c) self employed patients waiting for pre-booked NHS operations and procedures. \p Karin Smyth: The Department of Health and Social Care has indicated that it will not be possible to answer this question within the usual time period. An answer is being prepared and will be provided as soon as it is available.
wrans/answers2025-11-26 conversation_107
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_107

Helen Maguire:To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the taxpayer of raising NICE’s value for money threshold by 25 percent. \p Dr Zubir Ahmed: The pharmaceutical sector and the innovative medicines it produces are critical to our national interest, helping people access life changing treatments, reducing pressure on the health service over the longer-term, and ensuring we have a National Health Service that is fit for the future.

That is why through our Life Sciences Sector Plan, we have committed to working with industry to accelerate growth in spending on innovative medicines, compared to the previous decade. Our 10-Year Health Plan sets out how we will reform the National Institute for Health and Care Excellence.
wrans/answers2025-11-26 conversation_108
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_108

Mr Richard Holden:To ask the Secretary of State for Health and Social Care, whether the Government has (a) commissioned and (b) plans to commission studies using (i) genomic datasets, (ii) UK Biobank and (iii) Genomics England to estimate levels of (A) inbreeding and (B) runs of homozygosity and F coefficients across UK populations. \p Dr Zubir Ahmed: The Department has not, and has no plans to, commission such research via Genomics England, UK Biobank, Our Future Health, or the National Institute for Health and Care Research.
wrans/answers2025-11-26 conversation_109
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_109

Dr Ellie Chowns:To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure a sustainable funding settlement for hospice and palliative care in (a) Herefordshire and (b) the country. \p Stephen Kinnock: Integrated care boards (ICBs) are responsible for commissioning palliative care services to meet the reasonable needs of their population, which can include hospice services available within the ICB catchment. To support ICBs in this duty, NHS England has published statutory guidance and a service specification.

The Government is developing a Palliative Care and End of Life Care Modern Service Framework for England, due to be published in Spring 2026. I refer the hon. Member to the Written Ministerial Statement HCWS1087 I gave to the House on 24 November 2025.

Additionally, we are supporting the hospice sector with a £100 million capital funding boost for eligible adult and children’s hospices in England to ensure they have the best physical environment for care.   St Michael’s Hospice in Hereford is receiving £667,020 from this funding. We are also committing £80 million for children’s and young people’s hospices over the next three financial years, giving them stability to plan ahead and focus on what matters most, caring for their patients.
wrans/answers2025-11-26 conversation_110
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_110

James McMurdock:To ask the Secretary of State for Health and Social Care, if he will publish data on (a) the average waiting time from referral to first appointment and (b) other assessment capacity for ADHD in each Integrated Care Board. \p Dr Zubir Ahmed: For the first time, NHS England published management information on attention deficit hyperactivity disorder (ADHD) assessment waiting times at a national level on 29 May 2025 as part of its ADHD data improvement plan, and data is now released each quarter, with the latest release in August 2025.

Data on ADHD waiting times at an integrated care boards (ICB) level is not currently held centrally. NHS England has released technical guidance to ICBs to improve the recording of ADHD data, with a view to improving the quality of ADHD waits and diagnosis data as well as publishing more localised data. NHS England intends to publish data at an ICB level in 2026/27.

NHS England established an independent ADHD taskforce which brought together those with lived experience with experts from the National Health Service, education, charity, and justice sectors to get a better understanding of the challenges affecting those with ADHD, including in accessing services and support. The final report was published 6 November, and we will carefully consider its recommendations.
wrans/answers2025-11-26 conversation_111
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_111

Lewis Cocking:To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the adequacy of palliative care services in Broxbourne constituency. \p Stephen Kinnock: The Government is developing a Palliative Care and End of Life Care Modern Service Framework for England, due to be published in Spring 2026. I refer the hon. Member to the Written Ministerial Statement HCWS1087 I gave to the House on 24 November 2025.

We are supporting the hospice sector with a £100 million capital funding boost for eligible adult and children’s hospices in England to ensure they have the best physical environment for care. St Clare Hospice, which cares for patients from the Broxbourne constituency, is receiving £579,780 from this funding.

We are also providing £80 million for children’s and young people’s hospices over the next three financial years, giving them stability to plan ahead and focus on what matters most, caring for their patients. Haven House Children’s Hospice and Noah’s Ark Children's Hospice near Broxbourne will both benefit from this funding.
wrans/answers2025-11-26 conversation_112
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_112

Rupert Lowe:To ask the Secretary of State for Health and Social Care, to provide a breakdown of (a) total pay-outs (b) total value of claims to category A patients by (i) UK citizens (ii) asylum seekers for the financial year 24/25. \p Dr Zubir Ahmed: NHS Resolution manages clinical negligence and other claims against the National Health Service in England. This data is not held by NHS Resolution.
wrans/answers2025-11-26 conversation_113
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_113

Rupert Lowe:To ask the Secretary of State for Health and Social Care, what information his Department holds on the number of physicians responsible for medical malpractice which resulted in a pay-out in the 2024-25 financial year, broken down by nationality. \p Dr Zubir Ahmed: This data is not held by NHS Resolution.
wrans/answers2025-11-26 conversation_114
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_114

Rupert Lowe:To ask the Secretary of State for Health and Social Care, what the total (a) number of claims and (b) value of clinical negligence claims paid out in financial year 24/25 were attributed to language barrier issues. \p Dr Zubir Ahmed: This data is not held by NHS Resolution.
wrans/answers2025-11-26 conversation_115
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_115

Sir Oliver Dowden:To ask the Secretary of State for Health and Social Care, what steps his Department is taking to promote NHS innovation in robotics. \p Dr Zubir Ahmed: Robotics is one of the Department’s 10-Year Health Plan’s five "big bets” and by supporting the innovation pipeline from research through to adoption we aim to stimulate greater innovation and more rapid delivery of these technologies for improved patient outcomes and an improved health system.

To support adoption, our 10-Year Health Plan commits to expand surgical robot adoption over the next decade, support National Health Service trusts to increase robotic process automation, and scale the use of robots in pharmacy. We have also committed to establishing national registries for robotic surgery data from 2029 and to developing telesurgery networks. Earlier this year, NHS England published the first national guidance for the implementation of robotic assisted surgery (RAS) in the NHS, offering guidance on procurement, commissioning, implementation, training, and evaluation. A national steering committee is already in place to support the adoption of RAS, ensure safe implementation, and to oversee the training requirements for surgeons and surgical teams. The NHS aims to increase the number of robotic-assisted procedures to 500,000 by 2035, up from 70,000 in 2023/24.

The Department supports innovation in NHS robotics research by funding the National Institute for Health and Care Research (NIHR) and its NIHR HealthTech Research Centre (HRC) in Devices, Digital and Robotics, which is one of fourteen HRCs. This centre supports safe, effective, and efficient translation of new healthcare technologies, such as robotics, into routine care for NHS patients and follow-on social care.
wrans/answers2025-11-26 conversation_116
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_116

Sir Oliver Dowden:To ask the Secretary of State for Health and Social Care, what steps his Department is taking to promote NHS innovation in nano surgery. \p Dr Zubir Ahmed: As set out in the 10-Year Health Plan and Life Sciences Sector Plan, the Department encourages innovation in the health sector that helps to support the three big shifts in healthcare: moving care from hospitals to communities; transitioning from analogue to digital; and focusing on prevention over treatment.

The Department is actively supporting the development and evaluation of game-changing innovations as well as the adoption of technologies to give our world leading clinicians the technology and skills to improve outcomes for patients.

Improving innovation, adoption, and procurement of game-changing technology, including nano surgery, will help the National Health Service secure the best possible outcomes for patients whilst also delivering greater value-for-money and unlocking further economic growth. In addition, the National Cancer Plan will include further details on how we will improve outcomes for cancer patients, as well as speeding up diagnosis and treatment, ensuring patients have access to the latest treatments and technology, and ultimately drive up this country’s cancer survival rates.

The Department funds research through the National Institute for Health and Care Research (NIHR). As well as funding research directly through NIHR programmes, the Department also funds NIHR infrastructure which are centres of excellence and collaborations, services, and facilities to support health and care research.

The NIHR research infrastructure drives innovation through research across a range of health and care areas, including nano surgery. For example, the Surgical and Perioperative Care Translational Research Collaboration brings together NIHR infrastructure to develop new surgical interventions, improving patient safety and patient care before and after surgery.

The NIHR HealthTech Research Centres (HRCs) work with industry to develop medical devices, diagnostics, and digital technologies. The NIHR Accelerated Surgical Care HRC’s focus is on minimally invasive therapies which enable surgical care to be delivered with greater precision, minimal trauma, and improved outcomes.
wrans/answers2025-11-26 conversation_117
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_117

Joe Robertson:To ask the Secretary of State for Health and Social Care, what steps he is taking to help tackle increases in legal costs for clinical negligence. \p Dr Zubir Ahmed: The rising costs of clinical negligence claims against the National Health Service in England are of great concern to the Government. Costs have more than doubled in the last 10 years and are forecast to continue rising, putting further pressure on NHS finances.

As announced in the recently published 10-Year Health Plan for England, David Lock KC will be providing expert policy advice on the rising legal costs of clinical negligence and how we can improve patients’ experience of claims, ahead of a review by the Department in the autumn.

The results of David Lock’s work will inform future policy making in this area. No decisions on policy have been taken at this point, and the Government will provide an update on the work done and next steps in due course.
wrans/answers2025-11-26 conversation_118
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_118

Andrew Gwynne:To ask the Secretary of State for Health and Social Care, if he will implement standardised regulations for the (a) collection and (b) storage of rare cancer tissue samples obtained for the purposes of (i) medical treatment and (ii) future research. \p Dr Zubir Ahmed: The Human Tissue Authority (HTA) regulates organisations that remove, store, and use human tissue for scheduled purposes, including research and medical treatment.

Under the Human Tissue Act 2004, appropriate consent is always required to remove tissue from the deceased for research purposes. Tissue from living patients, for example biopsy or blood samples, can ordinarily be used for research only with the person's consent. The HTA ensures that it is removed and stored in an appropriate and well managed way.

Consent is not required for research on tissue from living patients if the samples are anonymised or coded to make sure patient or participant information is not identifiable, and the project has recognised ethics committee approval, or if the tissue samples were obtained before 1 September 2006, when the Human Tissue Act came into force.
wrans/answers2025-11-26 conversation_119
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_119

Andrew Gwynne:To ask the Secretary of State for Health and Social Care, if he will make it his policy to hold further meetings with (a) people affected by in-utero exposure to sodium valproate and (b) other relevant stakeholders on the progress made in implementing the recommendations outlined in the Hughes Report. \p Dr Zubir Ahmed: The Government is carefully considering the work by the Patient Safety Commissioner and her report, which set out options for redress for those harmed by valproate and pelvic mesh. This is a complex issue involving input from different Government departments. The Government will provide a further update to the Patient Safety Commissioner’s report.

The Department will consider further meetings with the community and relevant stakeholders, when we have a substantive update to ensure that discussions can be productive, as part of our work on these important issues.
wrans/answers2025-11-26 conversation_120
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_120

Helen Maguire:To ask the Secretary of State for Health and Social Care, what support he is providing to international medical and humanitarian partners to help with child amputees and life-altering injuries resulting from explosive weapons in conflict. \p Dr Zubir Ahmed: The Government recognises the appalling toll that explosive weapons in conflict zones exact on children. We recognise that children are among the most vulnerable in any crisis, suffering not only immediate physical harm but also enduring emotional and psychological trauma with lifelong consequences.

The Department has three strands of work which support those who have been injured in this way. First, we have partnered with the David Nott Foundation to support the delivery of life-saving medical training to Ukrainian clinicians under the International Medical Partnership initiative. Second, with the Foreign, Commonwealth and Development Office, we work closely with UKMed, a frontline medical age charity, who run clinical support programmes in both Ukraine and Gaza with National Health Service clinicians volunteering to provide life-saving medical aid to people affected by the conflict. Third, the Government has medically evacuated a small number of children from Gaza for specialist treatment in the United Kingdom.
wrans/answers2025-11-26 conversation_121
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_121

Dr Neil Shastri-Hurst:To ask the Secretary of State for Health and Social Care, what steps his Department is taking to ensure that concerns raised by NHS whistleblowers on patient safety are (a) recorded, (b) escalated and (c) reviewed. \p Dr Zubir Ahmed: There are a number of avenues through which healthcare workers can speak up and raise concerns, with established procedures in place to record, act on, and escalate issues as needed.

In England, more than 1,300 Freedom to Speak Up Guardians now support staff in speaking up. Their role involves working alongside governance, risk, and safety teams to ensure that speaking up translates into improvements in patient care, as well as identifying patterns and trends, for example, in patient safety incidents. Freedom to Speak Up Guardians collect and report anonymised data on the issues raised with them, including patient safety. This data is published by the National Guardian’s Office at the following link:

https://nationalguardian.org.uk/learning-resources/speaking-up-data/

The National Guardian’s Office and NHS England are ‘prescribed persons’, authorised to receive protected disclosures, including those in relation to safety and quality concerns. They are legally required to publish annual reports on protected disclosures and their outcomes.

Every National Health Service organisation in England should be following the national Freedom to Speak Up policy, which outlines minimum standards for handling and addressing concerns. This policy ensures that all reported concerns are considered carefully and investigated objectively when necessary.
wrans/answers2025-11-26 conversation_122
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_122

Mr Richard Holden:To ask the Secretary of State for Health and Social Care, whether any NHS trusts (a) collect and (b) are required to collect data on (i) child and infant mortality, (ii) congenital anomalies and (iii) other health outcomes attributable to parental consanguinity. \p Dr Zubir Ahmed: The responsibility to collect and report child deaths is held by the commissioning authority and local authorities’ Child Death Overview Panels (CDOPs), not National Health Service trusts. The Child Death Review statutory guidance requires NHS trusts to provide CDOPs with information to review a child’s death. This is done on an individual basis from the child's medical records and not from centrally held data within the NHS trust.

CDOPs and the National Child Mortality Database (NCMD) cannot comment on “other health outcomes attributable to parental consanguinity” because the CDOP process only applies to live born children who die before their 18th birthday.

The NCMD are preparing a thematic review of deaths to be published in 2026, which will report on the percentage of child death reviews that are attributed to chromosomal, genetic, and congenital anomalies, identifying consanguinity as a contributing factor.
wrans/answers2025-11-26 conversation_123
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_123

Dr Neil Shastri-Hurst:To ask the Secretary of State for Health and Social Care, if he will make an assessment of the prevalence of the use of Class (a) A, (b) B and (c) C drugs in NHS Mental Health Facilities. \p Dr Zubir Ahmed: We currently have no plans to make such an assessment. NHS England does not hold information or data related to the prevalence of illegal drug use across specialised mental health facilities.
wrans/answers2025-11-26 conversation_124
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_124

Sir Oliver Dowden:To ask the Secretary of State for Health and Social Care, what steps his Department is taking to promote NHS innovation in liquid biopsies. \p Dr Zubir Ahmed: The Government is committed to funding innovative technologies, including multi-cancer detection (MCD) tests such as liquid biopsies, to improve early cancer diagnosis rates for cancer patients in the National Health Service. The Office for Life Sciences’ Cancer Healthcare Goals programme is providing funding for a National Institute for Health and Care Research led trial to assess the clinical and cost effectiveness of MCD tests in primary care for patients presenting with non-specific abdominal symptoms. The programme has also provided £2.35 million of funding to support the research and development of the miONCO-Dx multi-cancer early detection test, which can identify 12 of the most lethal and common cancers at even the earliest stages of the disease course.
wrans/answers2025-11-26 conversation_125
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_125

Wendy Morton:To ask the Secretary of State for Health and Social Care, what recent assessment he has made of waiting times for children’s mental health services in the West Midlands; and what steps he is taking to reduce delays. \p Dr Zubir Ahmed: We know that too many children and young people are waiting too long for mental health support, and through our Plan for Change, we’re determined to give children and young people the best start in life, including in the West Midlands.

The Government is expanding access to mental health support teams in all schools and colleges to reach all pupils by 2029, ensuring that every pupil has access to early support services. This expansion will ensure that up to 900,000 more children and young people will have access to support from trained education mental health practitioners in 2025/26.

More widely, we are rolling out Young Futures Hubs. The Government’s first 50 Young Futures Hubs will bring together services at a local level to support children and young people, helping to ensure that young people can access early advice and wellbeing intervention. We will work to ensure that there is no wrong door for young people who need support with their mental health.

We have also committed to hiring 8,500 more mental health staff to reduce waiting times. Thus far, we have hired almost 7,000 extra mental health workers since July 2024.
wrans/answers2025-11-26 conversation_126
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_126

Jim McMahon:To ask the Secretary of State for Health and Social Care, what funding is provided to community based organisations in (a) Greater Manchester (b) Oldham to support men's mental health and wellbeing. \p Dr Zubir Ahmed: Mental health remains a core priority for England, including in Greater Manchester and Oldham. That's why nationally, we're investing £688 million to transform services, including £26 million to support people in mental health crisis. We are introducing Neighbourhood Mental Health Care for adults, which will bring together community, crisis, and inpatient mental health care into a single, seamless offer.

On 19 November, to coincide with International Men’s Health Day, we published the Men’s Health Strategy. The strategy includes tangible actions to improve access to healthcare, provide the right support to enable men to make healthier choices, develop healthy living and working conditions, foster strong social, community, and family networks, and address societal norms. It also considers how to prevent and tackle the biggest health problems affecting men of all ages, which include mental health and suicide prevention.

Through the Men’s Health Strategy, we are launching a groundbreaking partnership with the Premier League to tackle male suicide and improve mental health literacy, by embedding health messaging into the matchday experience. We also announced the Suicide Prevention Support Pathfinders programme for middle-aged men. This program will invest up to £3.6 million over three years in areas of England where middle-aged men are at most risk of taking their own lives and will tackle the barriers that they face in seeking support.

Responsibility for onward commissioning of mental health services sits with integrated care boards (ICB). It is the role of local ICB decision-makers to consider the implications of mental health services, specific to each geography and including the perspectives of healthcare professionals, patient advocacy groups, and local authorities.
wrans/answers2025-11-26 conversation_127
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_127

Matt Vickers:To ask the Secretary of State for Health and Social Care, what progress he has made on reducing delayed discharges from hospitals. \p Dr Zubir Ahmed: The Government is committed to tackling delayed discharges, to ensure patients do not remain in hospital longer than necessary and to free up hospital beds for patients that need them.

The Urgent and Emergency Care plan for 2025/26 sets as a priority that hospitals should tackle the delays in patients waiting to be discharged. They should eliminate discharge delays of more than 48 hours caused by in-hospital issues, and work with local authorities to tackle the longest delays, starting with those over 21 days, and to profile discharges by pathway to support local planning.

In January 2025, we published a new policy framework for the £9 billion Better Care Fund, which gives the National Health Service and local authorities accountability for setting and achieving joint goals for reducing discharge delays. Starting in the financial year 2026/27, we will reform the Better Care Fund, focusing on ensuring consistent joint NHS and local authority funding for services essential to integrated health and social care, such as hospital discharge, intermediate care, rehabilitation, and reablement.
wrans/answers2025-11-26 conversation_128
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_128

Mr Richard Holden:To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 11 November 2025 to Question 87431 on Congenital Abnormalities, what use is made of consanguinity data collected by NHS England through the Maternity Services Data Set in (a) regional public health planning, (b) genetic counselling services and (c) maternal and neonatal clinical risk assessments; and if he will publish any guidance issued to Integrated Care Boards which either references or is a result of that data. \p Dr Zubir Ahmed: The Office for Health Improvement and Disparities supports the delivery of national and regional priorities for prevention and health inequalities across the regional system. The NHS Genomic Medicine Service delivers genomic testing, guided by eligibility criteria set out in the National Genomic Test Directory, including in cases where genetic disorders may be linked to consanguinity. In maternity and neonatal services, clinicians carry out individual risk assessments of the women and babies in their care, and this may include discussing risks relating to parental genetic conditions, including consanguinity. These services do not use Maternity Services Dataset (MSDS) data, which is population-level. NHS England has published guidance on how to submit data about consanguinity and pregnancy to the MSDS, but NHS England is not planning to publish further guidance.
wrans/answers2025-11-26 conversation_129
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_129

Mr Gregory Campbell:To ask the Secretary of State for Health and Social Care, when he expects to receive the finalised report of the study into mesh complication surgery by the National Institute for Health and Care Research study. \p Dr Zubir Ahmed: The National Institute for Health and Care Research (NIHR), the research delivery arm of the Department, funds and supports a range of research to support women’s health conditions, including pelvic organ prolapse.

In May 2023 the NIHR commissioned a £1.6 million study to develop a validated patient reported outcome measure for prolapse, incontinence, and mesh complication surgery, to better understand the short and long-term health impacts of pelvic mesh surgery. Further information is available at the following link:

https://fundingawards.nihr.ac.uk/award/NIHR152187

This study is expected to report its findings in April 2026. The NIHR is also funding a study which will look at the long term effectiveness of surgical treatment for prolapse including pelvic mesh, with further information available at the following link:

https://fundingawards.nihr.ac.uk/award/NIHR133665

The NIHR continues to welcome funding applications for research into any aspect of human health including the use of vaginal mesh to treat pelvic organ prolapse. Applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money and scientific quality.
wrans/answers2025-11-26 conversation_130
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_130

Andrew Rosindell:To ask the Secretary of State for Health and Social Care, what steps are being taken to improve patient access to clinically effective new blood cancer treatments for NHS patients. \p Dr Zubir Ahmed: The National Institute for Health and Care Excellence (NICE) is the independent body responsible for developing authoritative, evidence-based recommendations for the National Health Service on whether new medicines represent a clinically and cost-effective use of resources. NHS England funds NICE-recommended cancer medicines from the Cancer Drugs Fund from the point of positive draft NICE guidance, bringing forward patient access by approximately five months than would otherwise be the case.

For the years 2023/24 to 2024/25, NICE recommended 25 medicines to treat blood cancer that are now available for the treatment of NHS patients.
wrans/answers2025-11-26 conversation_131
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_131

Victoria Collins:To ask the Secretary of State for Health and Social Care, what steps his Department is taking to develop national guidelines and quality standards for vision rehabilitation services; and if he will commission the National Institute for Health and Care Excellence to develop evidence-based standards in this area. \p Dr Zubir Ahmed: The National Institute for Health and Care Excellence (NICE) is the independent body that develops authoritative, evidence-based guidelines and quality standards for the health and care system on best practice. Topics for the development of NICE guidelines and quality standards are identified by the NICE prioritisation board, chaired by the NICE Chief Medical Officer, in line with its published prioritisation framework. NICE does not currently have any plans to develop a guideline or quality standard on vision rehabilitation. The NICE prioritisation board considered vision rehabilitation as a potential topic for the development of guidance in August 2024 and concluded that there is insufficient evidence in this area to develop useful guidance.
wrans/answers2025-11-26 conversation_132
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_132

Helen Maguire:To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the (a) availability and (b) affordability of hormone replacement therapy; and what steps he is taking to reduce regional disparities in access to menopause-related healthcare. \p Dr Zubir Ahmed: While there are no plans to review the inclusion of hormone replacement therapy (HRT) within the prescription charge exemption list, the HRT prescription pre-payment certificate is available for patients who are prescribed HRT on the National Health Service. The price of the HRT prescription pre-payment certificate (PPC) is the equivalent of two single prescription charges, currently £19.80, and covers all qualifying prescribed HRT medicines for the 12-month period of its validity, representing significant saving for patients compared to the single prescription charge. In financial year 2024/25, approximately 13.3 million HRT items were dispensed without charge, either because they were covered by the HRT PPC or the patient held an exemption from prescription charges.

There are over 70 HRT products, and the majority are in good supply. We are aware of shortages affecting Estradot (estradiol) patches. We are engaging with the supplier to expedite deliveries. We have issued guidance to healthcare professionals and Serious Shortage Protocols to enable community pharmacists to supply specified alternative estradiol patches.

We will also be asking local authorities to include menopause in the NHS Health Check from 2026. This will support eligible women from across England to access high quality information on the menopause, including advice on managing symptoms and where to seek support.

Further data on HRT prescriptions is available via the NHS Business Services Authority at the following link:

https://nhsbsa-opendata.s3.eu-west-2.amazonaws.com/hrt/hrt_June_2025_v001.html
wrans/answers2025-11-26 conversation_133
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_133

Helen Morgan:To ask the Secretary of State for Health and Social Care, if he will answer Questions (a) 81421 of 13 October 2025 on Covid-19 (b) 82016 of 14 October 2025 on prostate cancer screening and (c) 83882 of 21 October 2025 on health misinformation. \p Ashley Dalton: I refer the hon. Member to the answers I gave on 10 November 2025 to Question 81421, on 26 November 2025 to Question 82016, and on 19 November 2025 to Question 83882.
wrans/answers2025-11-26 conversation_134
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_134

Andrew Bowie:To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of the minutes of the Food Standards Agency’s Committee on Toxicity meeting of 25 March 2025; and whether he plans to hold discussions with the Food Standards Agency on the potential merits of (a) withdrawing its review of the safety of nitrites in processed meats, (b) publishing (i) correspondence, (ii) criteria and (iii) communications relating to its preparation and (c) commissioning a multidisciplinary study considering (A) animal, (B) human and (C) mechanistic evidence. \p Ashley Dalton: The Food Standards Agency (FSA) review of nitrates and nitrites as food additives is an important piece of work and will not be withdrawn. Its purpose was to summarise recent evidence from human studies to inform policy decisions, rather than to provide a full risk assessment. Current policy continues to align with NHS dietary advice, which recommends limiting consumption of red and processed meat, some of which contain nitrites, to 70g per day. We understand public concern about potential long-term health effects, including cancer risk, and remain committed to monitoring emerging evidence closely.

To maintain transparency, the full report, including its scope, search criteria, and details of the external contract, has been published on Government websites. This allows stakeholders and the public to see exactly how the review was conducted and how conclusions were reached.

The published report clearly sets out the methodology and criteria used, providing clarity and confidence in the process. While the FSA does not routinely publish internal correspondence or preparatory communications, due to the potential inclusion of commercially sensitive or personal information, the report itself provides full transparency on the evidence base and decision-making approach.

There are no plans to commission a broader multidisciplinary study. Existing permitted nitrite levels are based on robust international risk assessments and remain appropriate to protect public health. Commissioning a new study would require significant resource and is not justified without new evidence indicating a change in risk.
wrans/answers2025-11-26 conversation_135
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_135

Helen Morgan:To ask the Secretary of State for Health and Social Care, what steps he is taking to increase awareness of prostate-specific antigen tests among travel insurers. \p Ashley Dalton: PSA tests are blood tests that measure the amount of prostate specific antigen (PSA) in blood. Raised levels, often in combination with other symptoms, can be an indication of prostate cancer, though not exclusively. PSA tests have previously been used as a screening tool in asymptomatic populations, but their limitations mean they are not currently recommended for population-level screening. To find better ways of testing for prostate cancer, the Government is investing £16 million into the Prostate Cancer UK-led TRANSFORM screening trial, which aims to identify more effective approaches for detecting prostate cancer earlier.

While the Department has no plans to target insurers with information about PSA, the NHS website has clear and accurate information about PSA testing that can be referred to. Where someone has had a PSA test and they are concerned about their travel insurance, they should discuss this directly with their insurers. Different insurers may take a different view of the relevant factors in determining the price of insurance.
wrans/answers2025-11-26 conversation_136
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_136

Dr Caroline Johnson:To ask the Secretary of State for Health and Social Care, what steps he is taking to help increase the level of exercise undertaken by children. \p Ashley Dalton: The Government recognises the physical and mental health benefits that an active lifestyle can bring for children and young people.

The Department of Health and Social Care (DHSC) and the Department for Education co-fund the Primary School PE and Sport Premium, which enables schools to support children to have fun and move more through PE, sport, play and other forms of physical activity.

As committed to in the 10-Year Health Plan’s Prevention chapter, both departments are also working with the Department for Culture, Media and Sport to develop a new School Sport Partnerships network that will drive collaboration between schools and break down barriers for those who are less active, increasing opportunities for all children to move more. This is alongside wider cross sector action to reduce physical inactivity and get millions moving more. More information is available at the following link:

https://www.gov.uk/government/publications/10-year-health-plan-for-england-fit-for-the-future

In the summer, DHSC teamed up with Joe Wicks to launch ‘Activate’, a series of animated, fun five-minute workouts to help families and schools tackle inactivity among children.
wrans/answers2025-11-26 conversation_137
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_137

Jim Shannon:To ask the Secretary of State for Health and Social Care, how many people have been diagnosed with cardiovascular disease in the last year for which figures are available. \p Ashley Dalton: The Department does not hold information in the format requested. The cardiovascular disease (CVD) prevention audit provides a count of the number of people with a general practice record of CVD. This information is available publicly at the following link:

https://www.cvdprevent.nhs.uk/
wrans/answers2025-11-26 conversation_138
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_138

Nick Timothy:To ask the Secretary of State for Health and Social Care, what steps his department will take to raise awareness of the symptoms of gynaecological cancers. \p Ashley Dalton: NHS England is undertaking a wide range of activity to increase awareness of the symptoms of gynaecological cancer. NHS England relaunched the Help Us Help You cancer campaign in 2024, to encourage people to get in touch with their general practitioner if they notice symptoms that they are worried could turn out to be cancer.

NHS England and other National Health Service organisations, nationally and locally, publish information on the signs and symptoms of many different types of cancer, including gynaecological cancers.
wrans/answers2025-11-26 conversation_139
Source: hansard.parliament.uk (2025-11-26)

UK Parliament Hansard data: wrans/answers2025-11-26 conversation_139

Pippa Heylings:To ask the Secretary of State for Health and Social Care, if his Department will consider providing financial support for children living with Coeliac disease. \p Ashley Dalton: We recognise the pressures families face in managing coeliac disease, particularly the additional costs of maintaining a strict gluten-free (GF) diet, which is the only effective treatment for this condition.

The national prescribing position in England remains that GF bread and mixes can be provided to coeliac patients on a National Health Service prescription, and a wide range of these items continue to be listed in Part XV of the Drug Tariff. This means that prescribers can issue NHS prescriptions, based on a shared decision between prescriber and patient, while also being mindful of local and national guidance. Children under 16 years old, and those aged between 16 to 18 years old in full-time education, are entitled to free NHS prescriptions, ensuring that where integrated care boards support GF prescribing, eligible children can access these products without charge.